AP2000001971A0 - Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine. - Google Patents

Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine.

Info

Publication number: AP2000001971A0
Authority: AP; ARIPO
Prior art keywords: abacavir; lamivudine; zidovudine; pharmaceutical compositions; homogeneous pharmaceutical
Prior art date: 1998-04-29

Application number

APAP/P/2000/001971A

Other languages

English (en)

Inventor

Robin Currie

Sunil Jain

Allen Wayne Wood

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-29

Filing date

1999-04-26

Publication date

2000-12-31

1999-04-26 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-12-31 Publication of AP2000001971A0 publication Critical patent/AP2000001971A0/en

Links

229960004748 abacavir Drugs 0.000 title abstract 2
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 title 1
241000725303 Human immunodeficiency virus Species 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
230000000840 anti-viral effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
229960001627 lamivudine Drugs 0.000 abstract 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
229960002555 zidovudine Drugs 0.000 abstract 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

APAP/P/2000/001971A 1998-04-29 1999-04-26 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine. AP2000001971A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9809213.3A GB9809213D0 (en)	1998-04-29	1998-04-29	Pharmaceutical compositions
PCT/EP1999/002794 WO1999055372A1 (en)	1998-04-29	1999-04-26	Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine

Publications (1)

Publication Number	Publication Date
AP2000001971A0 true AP2000001971A0 (en)	2000-12-31

Family

ID=10831228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2000/001971A AP2000001971A0 (en)	1998-04-29	1999-04-26	Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine.

Country Status (23)

Country	Link
EP (1)	EP1083932A1 (id)
JP (1)	JP2002512979A (id)
KR (1)	KR20010043128A (id)
CN (1)	CN1411380A (id)
AP (1)	AP2000001971A0 (id)
AU (1)	AU4135599A (id)
BR (1)	BR9910071A (id)
CA (1)	CA2330391A1 (id)
EA (1)	EA200000997A1 (id)
EE (1)	EE200000646A (id)
GB (1)	GB9809213D0 (id)
HR (1)	HRP20000732A2 (id)
HU (1)	HUP0101622A3 (id)
ID (1)	ID26955A (id)
IL (1)	IL139181A0 (id)
IS (1)	IS5675A (id)
NO (1)	NO20005418L (id)
NZ (1)	NZ507745A (id)
PL (1)	PL343710A1 (id)
SK (1)	SK16212000A3 (id)
TR (1)	TR200003157T2 (id)
WO (1)	WO1999055372A1 (id)
ZA (1)	ZA200005922B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875773B1 (en)	1998-05-29	2005-04-05	Ben M. Dunn	Combination therapy for treatment of FIV infection
CA2374198A1 (en) *	1998-05-29	1999-12-02	Maki Arai	Combination therapy for treatment of fiv infection
GB9820417D0 (en) *	1998-09-18	1998-11-11	Glaxo Group Ltd	Antiviral combinations
US7074417B2 (en) *	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
DE60219965T2 (de) *	2002-04-23	2008-01-17	Lupin Ltd., Mumbai	Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
AR040242A1 (es) *	2002-06-04	2005-03-23	Glaxo Group Ltd	Composiciones farmaceuticas
CN100335125C (zh) *	2003-06-03	2007-09-05	上海现代药物制剂工程研究中心	杀毒抗菌用长效干扰素喷鼻粉剂
US20110104267A1 (en) *	2005-04-25	2011-05-05	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
WO2007013047A2 (en) *	2005-07-29	2007-02-01	Ranbaxy Laboratories Limited	Water-dispersible anti-retroviral pharmaceutical compositions
ES2279707B1 (es) *	2005-11-10	2008-06-01	Combino Pharm, S.L.	Formulaciones orales que comprenden 3'-azidonucleosidos.
CN101878032A (zh) *	2007-10-02	2010-11-03	埃默里大学	齐多夫定和针对hiv聚合酶中k65r突变选择的药剂的强力组合
WO2009092002A1 (en) *	2008-01-17	2009-07-23	Duquesne University Of The Holy Spirit	Antiretroviral drug formulations for treatment of children exposed to hiv/aids
UA105556C2 (uk) *	2010-01-27	2014-05-26	Віів Гелскер Компані	Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
CN104203275A (zh)	2010-06-09	2014-12-10	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
IN2014MN01907A (id)	2012-03-05	2015-07-10	Cipla Ltd
US10004721B2 (en)	2012-10-23	2018-06-26	Cipla Limited	Pharmaceutical antiretroviral composition
SMT202400092T1 (it)	2013-06-13	2024-05-14	Akebia Therapeutics Inc	Composizioni e metodi per il trattamento dell'anemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY115461A (en) *	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9622681D0 (en) *	1996-10-31	1997-01-08	Glaxo Group Ltd	Pharmaceutical compositions

1998
- 1998-04-29 GB GBGB9809213.3A patent/GB9809213D0/en not_active Ceased
1999
- 1999-04-26 IL IL13918199A patent/IL139181A0/xx unknown
- 1999-04-26 HR HR20000732A patent/HRP20000732A2/hr not_active Application Discontinuation
- 1999-04-26 JP JP2000545569A patent/JP2002512979A/ja active Pending
- 1999-04-26 ID IDW20002479A patent/ID26955A/id unknown
- 1999-04-26 TR TR2000/03157T patent/TR200003157T2/xx unknown
- 1999-04-26 PL PL99343710A patent/PL343710A1/xx unknown
- 1999-04-26 CA CA002330391A patent/CA2330391A1/en not_active Abandoned
- 1999-04-26 NZ NZ507745A patent/NZ507745A/en unknown
- 1999-04-26 BR BR9910071-1A patent/BR9910071A/pt not_active IP Right Cessation
- 1999-04-26 SK SK1621-2000A patent/SK16212000A3/sk unknown
- 1999-04-26 EA EA200000997A patent/EA200000997A1/ru unknown
- 1999-04-26 CN CN99807983A patent/CN1411380A/zh active Pending
- 1999-04-26 EP EP99924822A patent/EP1083932A1/en not_active Withdrawn
- 1999-04-26 KR KR1020007012021A patent/KR20010043128A/ko not_active Withdrawn
- 1999-04-26 EE EEP200000646A patent/EE200000646A/xx unknown
- 1999-04-26 AP APAP/P/2000/001971A patent/AP2000001971A0/en unknown
- 1999-04-26 HU HU0101622A patent/HUP0101622A3/hu unknown
- 1999-04-26 AU AU41355/99A patent/AU4135599A/en not_active Abandoned
- 1999-04-26 WO PCT/EP1999/002794 patent/WO1999055372A1/en not_active Ceased
2000
- 2000-10-20 IS IS5675A patent/IS5675A/is unknown
- 2000-10-23 ZA ZA200005922A patent/ZA200005922B/xx unknown
- 2000-10-27 NO NO20005418A patent/NO20005418L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200005922B (en)	2001-10-23
CA2330391A1 (en)	1999-11-04
ID26955A (id)	2001-02-22
NO20005418L (no)	2000-11-29
HRP20000732A2 (en)	2001-02-28
EA200000997A1 (ru)	2001-06-25
EE200000646A (et)	2002-04-15
HUP0101622A2 (hu)	2002-03-28
JP2002512979A (ja)	2002-05-08
NZ507745A (en)	2004-07-30
WO1999055372A1 (en)	1999-11-04
EP1083932A1 (en)	2001-03-21
SK16212000A3 (sk)	2001-07-10
NO20005418D0 (no)	2000-10-27
HUP0101622A3 (en)	2003-09-29
BR9910071A (pt)	2000-12-26
TR200003157T2 (tr)	2001-01-22
GB9809213D0 (en)	1998-07-01
CN1411380A (zh)	2003-04-16
IS5675A (is)	2000-10-20
AU4135599A (en)	1999-11-16
KR20010043128A (ko)	2001-05-25
IL139181A0 (en)	2001-11-25
PL343710A1 (en)	2001-08-27

Publication	Publication Date	Title
BG108439A (en)	2005-03-31	4'-substituted nucleosides
CA2366702A1 (en)	2000-10-12	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
TW371660B (en)	1999-10-11	Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
MY128463A (en)	2007-02-28	4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
IL132003A (en)	2005-08-31	Method for treating human immunodeficiency virus (hiv) in non-human mammals by administration of phytochemical compositions
GEP20053473B (en)	2005-03-25	High Potency Dihydroergotamine Compositions
WO2003063771A3 (en)	2005-07-07	N4-acylcytosine nucleosides for treatment of viral iinfections
CA2293470A1 (en)	1998-12-17	Benzimidazole derivatives
CA2321523A1 (en)	1999-10-14	Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
CA2445744A1 (en)	2002-11-28	Antiviral nucleoside derivatives
MY130035A (en)	2007-05-31	Antiviral compounds
EA200000997A1 (ru)	2001-06-25	Гомогенные фармацевтические композиции, содержащие абакавир, ламивудин и зидовудин
GEP20084377B (en)	2008-05-27	Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
WO2001078648A3 (en)	2003-12-18	6-methylnicotinamide derivatives as antiviral agents
MY119513A (en)	2005-06-30	Pharmaceutical compositions comprising lamivudine and zidovudine
MX9701273A (es)	1997-05-31	Succinato de (4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)2-ciclopenten-1-metanol como agente antiviral.
AU5848794A (en)	1994-08-29	Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
ES2105923A1 (es)	1997-10-16	Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
AU2002220594A1 (en)	2002-04-15	Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus
AU2880595A (en)	1996-01-25	Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
BG101175A (bg)	1997-08-29	Тройна анти-нiv комбинация
WO2006045616A3 (en)	2006-10-19	β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
AU6751794A (en)	1996-01-04	Extracts of piliostigma thonningii, the use thereof and formulations containing them
TW324663B (en)	1998-01-11	Interferon-ω(IFN-ω) as anti-HIV (human immune deficiency virus) agent
TW217986B (en)	1993-12-21	Compositions for the treatment of infection and disease caused by HBV